{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:53:21Z","timestamp":1766908401070,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OV5-170349","VRI-173022","VS1-175531"],"award-info":[{"award-number":["OV5-170349","VRI-173022","VS1-175531"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021824","name":"Government of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008921","name":"Ministry of Agriculture - Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["1072"],"award-info":[{"award-number":["1072"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.virusres.2025.199560","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:22:37Z","timestamp":1742329357000},"page":"199560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combination therapy enhances the antiviral activity of IFN-\u03bb against SARS-CoV-2 and MERS-CoV"],"prefix":"10.1016","volume":"355","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-2314","authenticated-orcid":false,"given":"Vahid Rajabali","family":"Zadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1685-3596","authenticated-orcid":false,"given":"Jocelyne M.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-3689","authenticated-orcid":false,"given":"M. Atif","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Santer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.virusres.2025.199560_bib0001","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"EPIC-HR trial investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.virusres.2025.199560_bib0002","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study","volume":"70","author":"Arabi","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.virusres.2025.199560_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM evidence"},{"issue":"2","key":"10.1016\/j.virusres.2025.199560_bib0004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.virusres.2025.199560_bib0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.medj.2022.04.002","article-title":"Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants","volume":"3","author":"Banerjee","year":"2022","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cld.2011.05.007","article-title":"1990-2010: two decades of interferon-based therapy","volume":"15","author":"Buti","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.virusres.2025.199560_bib0007","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","author":"Butler","year":"2022","journal-title":"Lancet North Am. Ed."},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.virusres.2025.199560_bib0009","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment","volume":"387","author":"Charness","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9380","key":"10.1016\/j.virusres.2025.199560_bib0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.virusres.2025.199560_bib0011","doi-asserted-by":"crossref","first-page":"20285","DOI":"10.2807\/ese.17.39.20285-en","article-title":"Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction","volume":"17","author":"Corman","year":"2012","journal-title":"Euro Surveill."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0012","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.virusres.2025.199560_bib0013","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.15252\/emmm.201606413","article-title":"IFN\u03bb is a potent anti-influenza therapeutic without the inflammatory side effects of IFN\u03b1 treatment","volume":"8","author":"Davidson","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"22","key":"10.1016\/j.virusres.2025.199560_bib0014","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial","volume":"321","author":"Davis","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.virusres.2025.199560_bib0015","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl Acad. Sci."},{"issue":"8","key":"10.1016\/j.virusres.2025.199560_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004250","article-title":"Infection with MERS-CoV causes lethal pneumonia in the common marmoset","volume":"10","author":"Falzarano","year":"2014","journal-title":"PLoS Pathog."},{"year":"2022","series-title":"Coronavirus (COVID-19) | Drugs","key":"10.1016\/j.virusres.2025.199560_bib0050"},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0017","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"41","key":"10.1016\/j.virusres.2025.199560_bib0018","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.1074\/jbc.AC120.013788","article-title":"Inhibition of SARS\u2013CoV-2 by type I and type III interferons","volume":"295","author":"Felgenhauer","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.virusres.2025.199560_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009705","article-title":"SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney","volume":"17","author":"Francis","year":"2021","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0020","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1038\/s41467-023-41761-1","article-title":"Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2","volume":"14","author":"Francis","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-\u03bb mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.virusres.2025.199560_bib0022","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.virusres.2025.199560_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12985-022-01783-5","article-title":"The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity","volume":"19","author":"Gu","year":"2022","journal-title":"Virol. J."},{"issue":"32","key":"10.1016\/j.virusres.2025.199560_bib0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203760119","article-title":"Interferon resistance of emerging SARS-CoV-2 variants","volume":"119","author":"Guo","year":"2022","journal-title":"Proc. Natl Acad. Sci."},{"issue":"15","key":"10.1016\/j.virusres.2025.199560_bib0026","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2025.199560_bib0027","first-page":"1","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0028","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","article-title":"Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0029","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","article-title":"Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys","volume":"149","author":"Jahrling","year":"1984","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virusres.2025.199560_bib0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0031","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40121-022-00633-9","article-title":"Interferon treatments for SARS-CoV-2: challenges and opportunities","volume":"11","author":"Jhuti","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.virusres.2025.199560_bib0032","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0033","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0034","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.virusres.2025.199560_bib0035","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-\u03bb: immune functions at barrier surfaces and beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.virusres.2025.199560_bib0038","article-title":"Interferon antagonists encoded by SARS-CoV-2 at a glance","author":"Lee","year":"2022","journal-title":"Med. Microbiol. Immunol. [Internet]"},{"issue":"2","key":"10.1016\/j.virusres.2025.199560_bib0039","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.09.007","article-title":"High potency of a bivalent human VH domain in SARS-CoV-2 animal models","volume":"183","author":"Li","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.virusres.2025.199560_bib0040","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/v14091991","article-title":"SARS-CoV-2 non-structural proteins and their roles in host immune evasion","volume":"14","author":"Low","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.virusres.2025.199560_bib0041","first-page":"2789","article-title":"Combination antiretroviral therapy for HIV infection","volume":"57","author":"Maenza","year":"1998","journal-title":"afp."},{"issue":"10229","key":"10.1016\/j.virusres.2025.199560_bib0042","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"Memish","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.virusres.2025.199560_bib0043","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0044","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.36233\/0507-4088-24","article-title":"[Interferon gamma in the treatment of patients with moderate COVID-19]","volume":"66","author":"Myasnikov","year":"2021","journal-title":"Vopr. Virusol."},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0046","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00210-021-02061-x","article-title":"Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies","volume":"394","author":"Nakhlband","year":"2021","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"5 Suppl 1","key":"10.1016\/j.virusres.2025.199560_bib0047","first-page":"S3","article-title":"National institutes of health consensus development conference statement: management of hepatitis C: 2002\u2013June 10-12, 2002","volume":"36","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0048","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200653","article-title":"COVID-19 and emerging viral infections: The case for interferon lambda","volume":"217","author":"Prokunina-Olsson","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.virusres.2025.199560_bib0049","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272826","article-title":"Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Ryoo","year":"2023","journal-title":"PLoS One"},{"issue":"0","key":"10.1016\/j.virusres.2025.199560_bib0052","article-title":"The Lancet Commission on lessons for the future from the COVID-19 pandemic","volume":"0","author":"Sachs","year":"2022","journal-title":"The Lancet [Internet]"},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0053","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1038\/s41467-022-34709-4","article-title":"Interferon-\u03bb treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity","volume":"13","author":"Santer","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.virusres.2025.199560_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008515","article-title":"Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells","volume":"16","author":"Santer","year":"2020","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0055","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2666-5247(21)00027-6","article-title":"Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics","volume":"2","author":"Schroeder","year":"2021","journal-title":"Lancet Microbe."},{"issue":"541","key":"10.1016\/j.virusres.2025.199560_bib0056","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.virusres.2025.199560_bib0057","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.virusres.2025.199560_bib0059","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7873","key":"10.1016\/j.virusres.2025.199560_bib0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: perspectives on the future trajectory of COVID-19","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature"},{"issue":"7897","key":"10.1016\/j.virusres.2025.199560_bib0061","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by SARS-CoV-2","volume":"602","author":"Thorne","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2025.199560_bib0062","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6515","key":"10.1016\/j.virusres.2025.199560_bib0063","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.virusres.2025.199560_bib0064","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.ymthe.2022.02.014","article-title":"The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.virusres.2025.199560_bib0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"51","key":"10.1016\/j.virusres.2025.199560_bib0066","doi-asserted-by":"crossref","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170225000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170225000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:10:40Z","timestamp":1762258240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170225000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":66,"alternative-id":["S0168170225000371"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2025.199560","relation":{},"ISSN":["0168-1702"],"issn-type":[{"type":"print","value":"0168-1702"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy enhances the antiviral activity of IFN-\u03bb against SARS-CoV-2 and MERS-CoV","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2025.199560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199560"}}